TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01983319

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial Direct Current Stimulation
Description: sham transcranial Direct Current Stimulation 30 min with CIMT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Description: 2 weeks of CIMT
Study: NCT01794247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Study: NCT05456048

Intervention type: DRUG
Intervention: VEN+HMA regimen
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study: NCT01779414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAT-ED Intervention
Description: Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
Study: NCT02944890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon Catheters(RESTORE DEB）

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Balloon Catheters(SeQuent® Please）
Study: NCT00968409

Intervention type: RADIATION
Group type: OTHER
Intervention: PET
Description: PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Testing
Description: Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels

Intervention type: OTHER
Group type: OTHER
Intervention: Safety Testing
Description: ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.

Intervention type: DRUG
Group type: OTHER
Intervention: F18-FFNP
Description: injection of F18-FFNP
Study: NCT04038073

Intervention type: DIAGNOSTIC_TEST
Intervention: Antistreptolysin O Test
Description: Test to evaluate of any histories of streptococcal infections

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Deoxyribonuclease B
Description: Test to evaluate of any histories of streptococcal infections

Intervention type: DIAGNOSTIC_TEST
Intervention: TLR, MyD88, IRAK-4 polymorphism
Description: Test to evaluate of the frequency and types of genetic alterations of innate immunity

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Basal Ganglia Antibody
Description: Test to evaluate the autoimmune component
Study: NCT01959529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected once daily subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected once daily subcutaneously (s.c., under the skin)
Study: NCT01555060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous gluconate
Description: daily capsule of ferrous gluconate containing 38 mg of elemental iron
Study: NCT01510093

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart 100 IE/ml
Description: 1.5 IE/hour/subject/visit. Each vist takes 10 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart 100 IE/ml
Description: 1.5 IE/hour/subject/visit. Each vist takes 10 hours
Study: NCT00329030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transplantation using rituxan/BEAM
Description: Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous transplantation using Bexxar/BEAM
Description: Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Study: NCT01544673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: 600 mg oral tablet twice daily for 4.5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg oral placebo twice daily for 4.5 days
Study: NCT02791464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
Study: NCT04252014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hookah tobacco messages
Description: Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
Study: NCT00216281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine augmented with atomoxetine up to 40 mg or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine augmented with atomoxetine up to 40 mg or placebo
Study: NCT03401320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ISM
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ISM
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ISM
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ISM
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
Study: NCT03064828

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT colonoscopy(normal dose)
Description: Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT colonoscopy (low dose)
Description: Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
Study: NCT03156829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Custom made splint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Splint + Cortico-steroid injection
Description: Splint + Cortico-steroid injection given in combination
Study: NCT00875914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF-ablation
Description: 4mm-tip catheter manually guided vs magneticallly navigated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF-ablation
Description: 4mm-tip catheter manually guided vs magneticallly navigated
Study: NCT02668666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
Study: NCT01238510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent technique: Routine fKBT
Description: Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only
Study: NCT04447794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Away Chatbot
Description: The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Away App
Description: The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies.
Study: NCT01601041

Intervention type: OTHER
Intervention: sonographic assessment of residual urine, urine culture
Description: residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage

Intervention type: OTHER
Intervention: sonographic assessment of residual urine, urine culture
Description: residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
Study: NCT01485653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
Study: NCT03789955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopic-guided TEB
Description: When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
Study: NCT03762668

Intervention type: DEVICE
Group type: OTHER
Intervention: Modified delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Modified delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens
Study: NCT03712306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice and advice on timing
Description: Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
Study: NCT04383730

Intervention type: DRUG
Intervention: Intravenous sedation
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices

Intervention type: DRUG
Intervention: Inhaled sedation
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
Study: NCT01271517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
Study: NCT03814265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: 440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
Study: NCT03737591

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
Study: NCT01324453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Conditioning + Primary PCI
Description: Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Primary PCI
Description: Routine Percutaneous Coronary Intervention as clinically indicated.
Study: NCT01794247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT02830035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time Ultrasound-guided
Description: Real-time ultrasound guided paramedian spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Landmark Technique
Description: Conventional anatomical landmark technique for paramedian spinal anesthesia
Study: NCT02292992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Pillow CPAP
Description: Nasal Pillow CPAP in extubated patients
Study: NCT04368455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)
Description: An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Same Way Same Day App
Description: An intervention that includes a self-directed app based curriculum
Study: NCT01453309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Saver
Description: Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Cell Saver
Description: Cell Saver will not be available during surgery
Study: NCT02623296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration of 2 matching placebo capsules from Day 1 to Day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of CYP450 substrates
Description: Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocktail of CYP450 substrates
Description: Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
Study: NCT02107430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa arm post radiotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa arm post radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy
Description: radiotherapy
Study: NCT03176277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 3mg once daily
Description: Part A initial dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 6mg once daily
Description: Part A 2nd dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 10mg once daily
Description: Part A 3rd dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 6mg + Venetoclax (70-400mg)
Description: Part D ONO-7475 + Venetoclax Combination
Study: NCT01379495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational program+telephone follow up
Description: burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
Study: NCT02761239

Intervention type: DEVICE
Group type: OTHER
Intervention: The NIM 3.0 Nerve Monitoring System
Description: Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
Study: NCT01983319

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint Induced Movement Therapy (CIMT)
Description: 2 weeks of CIMT
Study: NCT03738176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sesame Oil
Description: Sesame oil(80 gm NaCMC-20 gmSesame oil)
Study: NCT02668666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
Study: NCT00041548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide for inhalation
Description: given at 20 ppm for 1 hour then weaned off over 4 hours
Study: NCT00593502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
Study: NCT00335829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: embolization therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery infusion
Study: NCT06338111

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA Sepsis Biomarkers dosage
Description: Observational

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA Sepsis Biomarkers dosage
Description: Observational
Study: NCT02286726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT02981628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given Asparaginase Erwinia chrysanthemi

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study: NCT02365584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
Study: NCT00041548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: given at 20 ppm for one hour, then weaned off over four hours